EUVIMEDEUVIMED entdecken
Crossref

Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177 Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network

Laure Al Mansour, Louis De Mestier, Magalie Haissaguerre, Pauline Afchain, Julien Hadoux, Thierry Lecomte, David Morland, Anne Segolene Cottereau, Ophelie De Rycke, Ghoufrane Tlili, Jérémie Tordo, Marc Janier und 2 weitere

Journal of Nuclear Medicine · 2024-02 · 65 (2) · 258-263

DOI: 10.2967/jnumed.123.266063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 11.01.2024. Verfasst von Laure Al Mansour und 13 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Nucléaire, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Endocrine Gland Neoplasms, Intestinal Neoplasms, Organometallic Compounds. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A mesenteric mass (MM), characterized by fibrotic reaction, is present in most small-intestinal neuroendocrine tumors (SI-NETs). 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) has shown its efficacy in patients with progressive SI-NETs. However, because of specific tissue characteristics of desmoplastic MMs, we hypothesize that these lesions may be refractory to 177Lu-DOTATATE PRRT.

Methods

From the national French Groupe d'étude des Tumeurs Endocrines database, we identified patients with an advanced SI-NET and a MM (≥2 cm with a retractile aspect) of a SI-NET treated by at least 1 course of 177Lu-DOTATATE PRRT. The primary endpoint was a MM objective response rate (ORR) of less than 5%. Secondary endpoints were metabolic response, MM-related safety, and clinical response, as well as MM progression-free survival (PFS) and non-MM PFS.

Results

In total, 52 patients were included. The MM ORR was 4% (n = 2), and the non-MM ORR was 8% (n = 4). No patient had a MM metabolic response, and the non-MM metabolic response rate was 12% (n = 6). Among the 26 patients with baseline MM-related symptoms, 46% had a clinical response. Four patients presented with gastrointestinal complications during PRRT. The median MM-related PFS was not reached, and the non-MM PFS was 50.3 mo (95% CI, 38.2-61.7 mo).

Conclusion

This study confirms that 177Lu-DOTATATE PRRT does not lead to morphologic response on MMs (ORR < 5%). However, it allows MM stability, with few MM-related side effects, and has a relevant impact on MM-related symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsEndocrine Gland NeoplasmsIntestinal NeoplasmsOrganometallic CompoundsRadionuclide ImagingPositron-Emission TomographyHumansTreatment OutcomeOctreotideRadioisotopesReceptors, Peptide

Stichwörter der Autor:innen

177Lu-DOTATATEPRRTmesenteric massneuroendocrine tumorobjective response

Substanzen

copper dotatate CU-64OctreotideRadioisotopesReceptors, PeptideOrganometallic Compounds

Autor:innen und Institutionen

  • Service de Médecine Nucléaire, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.
  • Service de Pancréatologie et Oncologie Digestive, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Université Paris-Cité, Clichy, France.
  • Service d'Endocrinologie, Hôpital Haut-Lévêque, Université de Bordeaux, Pessac, France.
  • Service d'Oncologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Service d'Oncologie, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France.
  • Service de d'Hépato-gastro-entérologie et de Cancérologie Digestive, CHRU Hôpitaux de Tours, Tours, France.

Zitieren

APA

Al Mansour, L., De Mestier, L., Haissaguerre, M., Afchain, P., Hadoux, J., Lecomte, T., Morland, D., Cottereau, A. S., De Rycke, O., Tlili, G., Tordo, J., Janier, M., Deville, A., & Walter, T. (2024). Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177 Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network. Journal of Nuclear Medicine, 65(2), 258-263. https://doi.org/10.2967/jnumed.123.266063

Vancouver

Al Mansour L, De Mestier L, Haissaguerre M, Afchain P, Hadoux J, Lecomte T, et al. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177 Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network. Journal of Nuclear Medicine. 2024;65(2):258-263. doi:10.2967/jnumed.123.266063

BibTeX
@article{AlMansour2024,
  author = {Al Mansour, Laure and De Mestier, Louis and Haissaguerre, Magalie and Afchain, Pauline and Hadoux, Julien and Lecomte, Thierry and Morland, David and Cottereau, Anne Segolene and De Rycke, Ophelie and Tlili, Ghoufrane and Tordo, Jérémie and Janier, Marc and Deville, Agathe and Walter, Thomas},
  title = {Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177 Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {2},
  pages = {258--263},
  doi = {10.2967/jnumed.123.266063}
}
Kostenlos starten →